Literature DB >> 28586085

Enrichment of IL-17A+ IFN-γ+ and IL-22+ IFN-γ+ T cell subsets is associated with reduction of NKp44+ ILC3s in the terminal ileum of Crohn's disease patients.

J Li1, A L Doty1, Y Tang1, D Berrie1, A Iqbal2, S A Tan2, M J Clare-Salzler3, S M Wallet4, S C Glover1.   

Abstract

Crohn's disease (CD) is a chronic inflammatory condition of the human gastrointestinal tract whose aetiology remains largely unknown. Dysregulated adaptive immune responses and defective innate immunity both contribute to this process. In this study, we demonstrated that the interleukin (IL)-17A+ interferon (IFN)-γ+ and IL-22+ IFN-γ+ T cell subsets accumulated specifically in the inflamed terminal ileum of CD patients. These cells had higher expression of Ki-67 and were active cytokine producers. In addition, their proportions within both the IL-17A-producer and IL-22-producer populations were increased significantly. These data suggest that IL-17A+ IFN-γ+ and IL-22+ IFN-γ+ T cell subsets might represent the pathogenic T helper type 17 (Th17) population in the context of intestinal inflammation for CD patients. In the innate immunity compartment we detected a dramatic alteration of both phenotype and function of the intestinal innate lymphoid cells (ILCs), that play an important role in the maintenance of mucosal homeostasis. In the inflamed gut the frequency of the NKp44- CD117- ILC1s subset was increased significantly, while the frequency of NKp44+ ILC3s was reduced. Furthermore, the frequency of human leucocyte antigen D-related (HLA-DR)-expressing-NKp44+ ILC3s was also reduced significantly. Interestingly, the decrease in the NKp44+ ILC3s population was associated with an increase of pathogenic IL-17A+ IFN-γ+ and IL-22+ IFN-γ+ T cell subsets in the adaptive compartment. This might suggest a potential link between NKp44+ ILC3s and the IL-17A+ IFN-γ+ and IL-22+ IFN-γ+ T cell subsets in the terminal ileum of CD patients.
© 2017 British Society for Immunology.

Entities:  

Keywords:  Crohn's disease; T cells; innate lymphoid cells

Mesh:

Substances:

Year:  2017        PMID: 28586085      PMCID: PMC5588779          DOI: 10.1111/cei.12996

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  38 in total

Review 1.  Crohn's disease.

Authors:  Fergus Shanahan
Journal:  Lancet       Date:  2002-01-05       Impact factor: 79.321

2.  Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.

Authors:  Wolfgang Hueber; Bruce E Sands; Steve Lewitzky; Marc Vandemeulebroecke; Walter Reinisch; Peter D R Higgins; Jan Wehkamp; Brian G Feagan; Michael D Yao; Marek Karczewski; Jacek Karczewski; Nicole Pezous; Stephan Bek; Gerard Bruin; Bjoern Mellgard; Claudia Berger; Marco Londei; Arthur P Bertolino; Gervais Tougas; Simon P L Travis
Journal:  Gut       Date:  2012-05-17       Impact factor: 23.059

3.  Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study.

Authors:  Walter Reinisch; Williem de Villiers; László Bene; László Simon; István Rácz; Seymour Katz; István Altorjay; Brian Feagan; Dennis Riff; Charles N Bernstein; Daniel Hommes; Paul Rutgeerts; Antoine Cortot; Michael Gaspari; May Cheng; Tillman Pearce; Bruce E Sands
Journal:  Inflamm Bowel Dis       Date:  2010-02       Impact factor: 5.325

Review 4.  Innate lymphoid cells as regulators of immunity, inflammation and tissue homeostasis.

Authors:  Christoph S N Klose; David Artis
Journal:  Nat Immunol       Date:  2016-06-21       Impact factor: 25.606

5.  Imbalance of NKp44(+)NKp46(-) and NKp44(-)NKp46(+) natural killer cells in the intestinal mucosa of patients with Crohn's disease.

Authors:  Tetsuro Takayama; Nobuhiko Kamada; Hiroshi Chinen; Susumu Okamoto; Mina T Kitazume; Jonathan Chang; Yumi Matuzaki; Sadafumi Suzuki; Akira Sugita; Kazutaka Koganei; Tadakazu Hisamatsu; Takanori Kanai; Toshifumi Hibi
Journal:  Gastroenterology       Date:  2010-06-01       Impact factor: 22.682

6.  Cross-talk between RORγt+ innate lymphoid cells and intestinal macrophages induces mucosal IL-22 production in Crohn's disease.

Authors:  Shinta Mizuno; Yohei Mikami; Nobuhiko Kamada; Tango Handa; Atsushi Hayashi; Toshiro Sato; Katsuyoshi Matsuoka; Mami Matano; Yuki Ohta; Akira Sugita; Kazutaka Koganei; Rikisaburo Sahara; Masakazu Takazoe; Tadakazu Hisamatsu; Takanori Kanai
Journal:  Inflamm Bowel Dis       Date:  2014-08       Impact factor: 5.325

7.  Distinct immune signatures in the colon of Crohn's disease and ankylosing spondylitis patients in the absence of inflammation.

Authors:  Elliott T J Dunn; Edward S Taylor; Simon Stebbings; Michael Schultz; A Grant Butt; Roslyn A Kemp
Journal:  Immunol Cell Biol       Date:  2015-12-09       Impact factor: 5.126

8.  Comprehensive intestinal T helper cell profiling reveals specific accumulation of IFN-γ+IL-17+coproducing CD4+ T cells in active inflammatory bowel disease.

Authors:  Anna-Maria Globig; Nadine Hennecke; Bianca Martin; Maximilian Seidl; Günther Ruf; Peter Hasselblatt; Robert Thimme; Bertram Bengsch
Journal:  Inflamm Bowel Dis       Date:  2014-12       Impact factor: 5.325

9.  IL-12- and IL-23-induced T helper cell subsets: birds of the same feather flock together.

Authors:  Estelle Bettelli; Vijay K Kuchroo
Journal:  J Exp Med       Date:  2005-01-17       Impact factor: 14.307

Review 10.  Maintenance of Immune Homeostasis through ILC/T Cell Interactions.

Authors:  Nicole von Burg; Gleb Turchinovich; Daniela Finke
Journal:  Front Immunol       Date:  2015-08-13       Impact factor: 7.561

View more
  14 in total

Review 1.  Plasticity of innate lymphoid cell subsets.

Authors:  Suzanne M Bal; Korneliusz Golebski; Hergen Spits
Journal:  Nat Rev Immunol       Date:  2020-02-27       Impact factor: 53.106

2.  Dysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer.

Authors:  Jeremy Goc; Mengze Lv; Nicholas J Bessman; Anne-Laure Flamar; Sheena Sahota; Hiroaki Suzuki; Fei Teng; Gregory G Putzel; Gerard Eberl; David R Withers; Janelle C Arthur; Manish A Shah; Gregory F Sonnenberg
Journal:  Cell       Date:  2021-08-17       Impact factor: 66.850

Review 3.  Helper-Like Type-1 Innate Lymphoid Cells in Inflammatory Bowel Disease.

Authors:  Diana Coman; Isabelle Coales; Luke B Roberts; Joana F Neves
Journal:  Front Immunol       Date:  2022-06-23       Impact factor: 8.786

Review 4.  Functional interactions between innate lymphoid cells and adaptive immunity.

Authors:  Gregory F Sonnenberg; Matthew R Hepworth
Journal:  Nat Rev Immunol       Date:  2019-07-26       Impact factor: 53.106

Review 5.  Should We Divide Crohn's Disease Into Ileum-Dominant and Isolated Colonic Diseases?

Authors:  Parambir S Dulai; Siddharth Singh; Niels Vande Casteele; Brigid S Boland; Jesus Rivera-Nieves; Peter B Ernst; Lars Eckmann; Kim E Barrett; John T Chang; William J Sandborn
Journal:  Clin Gastroenterol Hepatol       Date:  2019-04-19       Impact factor: 13.576

Review 6.  Group 3 Innate Lymphoid Cells: Communications Hubs of the Intestinal Immune System.

Authors:  David R Withers; Matthew R Hepworth
Journal:  Front Immunol       Date:  2017-10-16       Impact factor: 7.561

7.  Commensal and Pathogenic Bacteria Indirectly Induce IL-22 but Not IFNγ Production From Human Colonic ILC3s via Multiple Mechanisms.

Authors:  Moriah J Castleman; Stephanie M Dillon; Christine M Purba; Andrew C Cogswell; Jon J Kibbie; Martin D McCarter; Mario L Santiago; Edward Barker; Cara C Wilson
Journal:  Front Immunol       Date:  2019-03-29       Impact factor: 7.561

Review 8.  Gut Microbiota Modulation on Intestinal Mucosal Adaptive Immunity.

Authors:  Li Wang; Limeng Zhu; Song Qin
Journal:  J Immunol Res       Date:  2019-10-03       Impact factor: 4.818

9.  Integrating Pharmacology and Microbial Network Analysis with Experimental Validation to Reveal the Mechanism of Composite Sophora Colon-Soluble Capsule against Ulcerative Colitis.

Authors:  Yuxuan Ding; Mingjun Chen; Qiying Wang; Lu Gao; Yang Feng; Shida Wang; Zitian Song; Zhanqi Tong
Journal:  Evid Based Complement Alternat Med       Date:  2020-04-20       Impact factor: 2.629

10.  The Crohn's disease polymorphism, ATG16L1 T300A, alters the gut microbiota and enhances the local Th1/Th17 response.

Authors:  Aleksander Kostic; Wendy S Garrett; Ramnik J Xavier; Sydney Lavoie; Kara L Conway; Kara G Lassen; Humberto B Jijon; Hui Pan; Eunyoung Chun; Monia Michaud; Jessica K Lang; Carey Ann Gallini Comeau; Jonathan M Dreyfuss; Jonathan N Glickman; Hera Vlamakis; Ashwin Ananthakrishnan
Journal:  Elife       Date:  2019-01-22       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.